Mediators involved in the generation of pain in patients with cancer are poorly understood. Using a combined molecular, pharmacologic, behavioral, and genetic approach, we have identified a novel mechanism of cancer-dependent allodynia induced by protease-activated receptor 2 (PAR2). Here we show that human head and neck carcinoma cells have increased levels of proteolytic activity compared to normal human cell controls. Supernatant from human carcinoma cells, but not controls, caused marked and prolonged mechanical allodynia in mice, when administered into the hindpaw. This nociceptive effect was abolished by serine protease inhibition, diminished by mast cell depletion and absent in PAR2-deficient mice. In addition, non-contact co-culture of trigeminal ganglion neurons with human head and neck carcinoma cells increased the proportion of neurons that exhibited PAR2-immunoreactivity. Our results point to a direct role for serine proteases and their receptor in the pathogenesis of cancer pain. This previously unrecognized cancer pain pathway has important therapeutic implications wherein serine protease inhibitors and PAR2 antagonists may be useful for the treatment of cancer pain.
Introduction
Pain is one of the problems that patients suffering with cancer fear most [16] . Cancer often produces severe pain and dysfunction secondary to mechanical hypersensitivity in humans [7, 34, 42, 52] . Following the rapid development of opioid tolerance there are no pharmacologic agents available to treat intractable cancer pain. Given that cancer is often incurable, yet can cause significant pain, research should be focused on the management of cancer pain and improving quality of life. A major obstacle to the effective treatment of cancer pain is that the nociceptive mediators and their mechanisms of action are unknown. Nociceptive mediators secreted by the cancer and inflammatory cells within the cancer microenvironment are proposed to sensitize and activate primary afferents leading to pain [12, 18, 39] . Metabolic products of arachidonic acid are produced by a number of different cancer types, including head and neck squamous cell carcinoma (SCC) [29, 57] , and are well known to sensitize nociceptive primary afferents [6, 58, 59] . While medications including nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors prevent the production of arachidonic acid metabolites, these medications are often ineffective in alleviating cancer pain [41, 55] . The poor efficacy of these drugs suggests that other peripheral nociceptive mediators contribute to the extreme intensity of cancer pain.
We sought to determine whether mediators released by human head and neck cancer cells produce hypersensitivity symptoms (mechanical allodynia) in animals that may occur in humans secondary to cancer pain. We focused our attention on proteases and their receptors because carcinomas and associated inflammatory cells (e.g. mast cells) in the cancer microenvironment produce and secrete proteases that are critical for carcinogenesis [2, 61] . These proteases might act through protease-activated receptors (PARs), a family of G-protein coupled receptors (PAR1-4), whose activation by proteases expose a tethered ligand that binds peptide residues and initiates signal transduction [38, 48, 54] . PAR2 is of particular interest in peripheral nociception because it is expressed on nociceptive afferents, is preferentially activated by trypsin and related serine proteases, including mast cell tryptase, and its activation leads to the release of substance P (SP), which produces hyperalgesia [8, 44, 48, 51] . However, the role of proteases and PAR2 in cancer pain is not known. Here we show evidence for a crucial role for serine proteases released by human head and neck cancer cells as mediators that generate hypersensitivity symptoms via a PAR2-dependent mechanism. 
